Recent news on Delatestryl

Indevus to Present at the 2007 FBR Growth Conference  -  May 23, 2007
Earthtimes.orgThe Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male

Alkermes and Indevus Announce Initiation of Phase 2a Clinical ...  -  26 Apr 2007
PipelineReview.com (press release),DELATESTRYL(R) is Indevus' registered trademark for its DELATESTRYL product. Indevus has pending trademark applications for SANCTURA XR.

Indevus Announces Submission of Supplemental NDA to Reintroduce ...  -  Apr 19, 2007
PipelineReview.com (press release),The Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male

Valera Pharmaceuticals, Inc. Announces Intention to Delist From ...  -  Apr 6, 2007
Web Services Journal,The Company's marketed products include SANCTURA® for overactive bladder and DELATESTRYL® to treat male hypogonadism. The compounds in development include

Valera Pharmaceuticals, Inc. Announces Intention to Delist From ...  -  Apr 6, 2007
Genetic Engineering News (press release),The Company's marketed products include SANCTURA(R) for overactive bladder and DELATESTRYL(R) to treat male hypogonadism. The compounds in development

Biotech Day In Review: MedImmune Puts Itself Up For Sale  -  Apr 12, 2007
Seeking Alpha,Indevus markets Sanctura for overactive bladder, Delatestryl for male hypgogonadism and other drugs. Valera is developing hydrogel-based implants for

Indevus to Present at CIBC Annual Biotechnology & Specialty ...  -  Apr 5, 2007
PR-Inside.com (Pressemitteilung),...bladder, which it co-promotes with its partner Esprit Pharma, Inc. and DELATESTRYL(R) to treat male hypogonadism. The compounds in development include

Indevus Reports That Interim Review of NEBIDO(R) Phase III Data ...  -  27 Mar 2007
PipelineReview.com (press release),The Company's marketed products include SANCTURA(R) for overactive bladder, which it co-promotes with its partner Esprit Pharma, Inc. and DELATESTRYL(R) to

Indevus Pharmaceuticals Announces First Quarter Fiscal 2007 ...  -  Feb 7, 2007
PR Newswire (press release),Cost of product revenue relates primarily to sales of SANCTURA to Esprit at cost and costs associated with DELATESTRYL. Included in the cost of product

Indevus Pharmaceuticals To Announce First Quarter Fiscal 2007 ...  -  Feb 1, 2007
PR Newswire (press release),About DELATESTRYL DELATESTRYL(R) is an injectable testosterone preparation for the treatment of male hypogonadism. DELATESTRYL is contraindicated in men

Indevus Pharmaceuticals To Announce First Quarter Fiscal 2007 ...  -  Feb 2, 2007
Drug Newswire (press release),DELATESTRYL(R) is an injectable testosterone preparation for the treatment of male hypogonadism. DELATESTRYL is contraindicated in men with carcinomas of

Indevus Pharmaceuticals To Announce First Quarter Fiscal 2007 ...  -  Feb 1, 2007
Yahoo! News (press release)The Company's marketed products include SANCTURA® for overactive bladder, which it co-promotes with its partner Esprit Pharma, Inc. and DELATESTRYL® to

Alkermes and Indevus Announce Joint Collaboration to Develop ...  -  Jan 5, 2007
PipelineReview.com (press release),The Company’s marketed products include SANCTURA® for overactive bladder and DELATESTRYL® to treat male hypogonadism. The compounds in development include

Alkermes and Indevus Announce Joint Collaboration to Develop ...  -  Jan 4, 2007
PharmaLive.com (press release),The Company's marketed products include SANCTURA(R) for overactive bladder and DELATESTRYL(R) to treat male hypogonadism. The compounds in development

FDA Accepts New Drug Application For SANCTURA XR(TM) Submitted By ...  -  Dec 25, 2006
Medical News Today (press release),...conditions. The Company's marketed products include SANCTURA(R) for overactive bladder and DELATESTRYL(R) to treat male hypogonadism. ...

Indevus Pharmaceuticals Announces Fiscal 2006 Year End and Fourth ...  -  Dec 7, 2006
Yahoo! News (press release)2006 Highlights -- In January, the Company completed its acquisition of the US rights to DELATESTRYL from Savient Pharmaceuticals. ...

Indevus Pharmaceuticals Announces Fiscal 2006 Year End and Fourth ...  -  Dec 7, 2006
PR Newswire (press release),...economic interest in aminocandin's success." 2006 Highlights -- In January, the Company completed its acquisition of the US rights to DELATESTRYL from Savient ...

Indevus Pharmaceuticals Announces Fiscal 2006 Year End and Fourth ...  -  Dec 7, 2006
Drug Newswire (press release),...received from the Company's partner, $7.7 million of SANCTURA royalties, $8.8 million in sales force subsidy and $2.7 million from net sales of DELATESTRYL. ...

Indevus Pharmaceuticals to Acquire Valera Pharmaceuticals  -  Dec 12, 2006
Yahoo! News (press release)...focused portfolio of marketed and late stage products, including SANCTURA® and SANCTURA XR(TM) for overactive bladder, NEBIDO® and DELATESTRYL® for male ...

Indevus Pharmaceuticals to Acquire Valera Pharmaceuticals  -  Dec 12, 2006
Genetic Engineering News (press release),...focused portfolio of marketed and late stage products, including SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, NEBIDO(R) and DELATESTRYL(R) for male ...

Indevus Pharmaceuticals to Announce Fiscal 2006 Financial Results ...  -  Dec 5, 2006
Earthtimes.orgThe Company currently co-promotes SANCTURA(R) for overactive bladder and markets DELATESTRYL(R) to treat male hypogonadism and currently has six compounds in ...

Indevus ends fiscal year with 50 percent revenue boost  -  Dec 7, 2006
Boston Business Journal,Among Indevus' 2006 highlights: The company acquired the US marketing rights to Delatestryl, a drug produced by Savient Pharmaceuticals to treat male ...

Indevus Pharmaceuticals (IDEV) Misses Q4 EPS by 2c  -  Dec 7, 2006
StreetInsider.com (subscription),...received from the Company's partner, $7.7 million of SANCTURA royalties, $8.8 million in sales force subsidy and $2.7 million from net sales of DELATESTRYL.

Valera Jumps on Buyout Deal  -  Dec 12, 2006
BusinessWeekThe Lexington (Mass.) outfit already markets Delatestryl, another therapy for male hypogonadism which requires more frequent injections than Nebido. ...

Indevus To Acquire Valera For $120 Mln In Stock Transaction Plus ...  -  Dec 12, 2006
Trading Markets,...our current focused portfolio of marketed and late stage products, including Sanctura and Sanctura XR for overactive bladder, Nebido and Delatestryl for male ...

FDA Accepts New Drug Application for SANCTURA XR(TM) Submitted by ...  -  Dec 13, 2006
Yahoo! News (press release)...conditions. The Company's marketed products include SANCTURA® for overactive bladder and DELATESTRYL® to treat male hypogonadism. ...

Indevus sees net loss remaining in mid-teens for next few qrtrs  -  Dec 7, 2006
ReutersSales of Delatestryl, a marketed injectable testosterone preparation for the treatment of male hypogonadism, are expected to come down in 2007 due to generic ...

Indevus and Sanofi-Aventis' Spin-Out Company, Novexel, Announce ...  -  Dec 5, 2006
Yahoo! News (press release)The Company currently co-promotes SANCTURA® for overactive bladder and markets DELATESTRYL® to treat male hypogonadism and currently has six compounds in ...

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional